Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Years of hype and pump no longer works when nothing material comes of it. Thanks to today's PR I no longer have a position here. High trading fees for OTC pennies doesn't help either.
4.63 billion market cap. $5.34 loss per share. $20 BV. Zero revenues. Impressive
https://finviz.com/quote.ashx?t=MDGL&p=d
SHMN needs to take lessons from them on how to pump up their stock cuz what they're doing isn't working.
Without cas9 crispr gene therapy FDA approval for any use ABBIE also had no useful purpose. That's changed now and the door's wide open for approval for other treatments. ABBIE improves the accuracy and efficacy of those treatments, is my understanding.
December 8, 2023
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Sickle Cell Disease.
But I'm just a dumbass stock trader with an interest in medical science so what do I know.
Regardless, they chose SHMN to establish a distributive presence in the US. What's in it for Sohm remains to be seen.
Stallion labs has been manufacturing Levetiracetam since 2009. In 15 years they should already have a large market share.
It is my understanding SHMN now has the exclusive rights to distribute the Stallion brand of the drug to the share of the market Stallion has already established. I also believe that if Stallion thought SHMN didn't have the distribution capabilities they wouldn't have struck an exclusive deal with them to do so.
Stirring up some business at DCAT along with an ABBIE licencing deal could really get things going here.
It couldn't be more simple. Shareholders are stakeholders. PERIOD! It's never been been otherwise. Some think the word stakeholder is a more sophisticated reference to shareholder, even though they are one and the same.
If you want to be just a stakeholder and not a shareholder, then sell your shares, loan the company a few million and you become a stakeholder only.
Are you still saying shareholders are not stakeholders?
A stakeholder is anyone who is impacted by a company or organization's decisions, regardless of whether they have ownership in that company. Shareholders are those who have partial ownership of a company because they have bought stock in it. All shareholders are stakeholders, but not all stakeholders are shareholders.
Remains to be seen what their return will be on whatever portion of the $5mm funding has been used so far.
Only certainty is there will be plenty of positive or negative comments whatever it is. Currently, their success revolves around ABBIE and how well it plays out. Anything else will be gravy.
Right now I'd like to know what Aguilar's successful trip to Japan was all about. Was it a successful business trip (ABBIE) or a successful vacation?
Hmmm, looks like someone unloaded and someone loaded. One of those groups is going to be very disappointed very soon.
Also gotta feeling Sohm's email box will be blowing up very soon, if not already.
$SHMN, strong buying out of nowhere for no reason could indicate an insider found a reason to add.
Anyway, she's building a stronger base. IMO
Curious to see what value SOHM's accountants place on ABBIE and how that reflects on SHMN's book value. May not be much till contracts start rolling in but who knows till the next balance sheet is filed. With the success and value of gene editing finally starting to surface and the charge per treatment shown in today's PR, it could be considerable just as it currently sits.
OTC pennies tend to be very quiet thru end of year holiday season. SHMN has never deviated from that tendency. If they remain silent for some time after holiday end, then there might be reason for doubts.
In the meantime anyone that sold on the last little pop and didn't re-enter lower yet, times running short.
Leaves me thinking there might be a SHMN/Universal Sequencing Inc partnership in the works. Or maybe more.
I saw where Universal Sequencing Technology does between 10mm and 50mm in revenues so if there is a partnership to be announced it could be quite lucrative for SHMN and UST.
Correction: 186,000,000
Looking at it another way, more than $730,000 in money volume has traded since the funding PR in July. In that time the price has gone from .0006 to.0019, up about 300% interspersed with a few expected small profit taking pull backs. The biggest day was 186,000 shares the day ABBIE was announced.
I suspect since then small volume accumulation has taken place and locked up much of the float till God knows when. Maybe till it starts setting all time highs? Except with many that's a buy signal so it might not be that big a deal. Plus, it's held up reasonably well so far thru the tax loss selling.
Time will tell.
They projected earning several million in 2024. Earnings and profits are the same. Several could be anywhere from 3M to tens of millions depending on ABBIE. Or for that matter, how much in orders they already have waiting on MFG.
Believe it or not, Nov sees the greatest amount of TLS. Thought is always that get out with the loss first part of Nov, then slowly get back in after the 30 days expires. Not that Dec won't be sprinkled with more of it, of course it will, but the right PR could easily turn the table 180 degrees. And there's plenty of potential for that.
So sell at your own risk.
Today's tweets came out of nowhere and kicked a few people off the fence. That's the problem here, to many think they've got time and it will get knocked back down and offer a better buy later. But they're confused with OTC's that constantly dilute into news. Not so in this case. Gotta feeling 12's were the last shot at getting in lower cuz news keeps flowing and getting better each time. Not hard to figure out there's bigger and better news to come
0016 is above the consolidation channel before the drop to 0006 so it's now or deep regrets later. It could retest 0012 but not for long and probably not with volume.
$SHMN all tech indicators currently positive, 5,10 & 20 MAs in buy mode, 50 & 200 MAs are both pointing upward, w/ the 50 in strong uptrend.
The biggest positive is PPS broke out of an ascending triangle on above average volume (very bullish). It may drop back to test the strength of the breakout on low volume, but, IMO, the uptrend will remain strong based on all the positives in the pipeline.
Strong buy, IMO.
All major achievements in last 3 months included in q3 report.
Except the $5 million loan. Anyone know why?
Cost is higher than OTCM but if they want to play with the big boys they'll have to play by big boy rules. Most institutional investors won't go near an OTC penny if they aren't SEC registered.
If SHMN has confidence in its future it's something they should do.
I agree. Things needing done to bring them to success, they are now doing. While ABBIE sits on the back burner slowly coming to a boil.
Q3 disclosure report will be out middle of Nov, but if no information on what they've done so far in Q3 isn't included in it, and it's just another copy and paste per the usual, it could get ugly and painful real fast sitting thru TLS. They need to get with it, follow thru and make sure what they've done so far and are currently doing more of gets broadcast far and wide. Hard to TLS when given good reason to hold and selling becomes a bigger risk.
If the 3 new hires to the executive team got the 25mm shares they've got skin in the game and can be expected to work hard to get rewarded for their efforts.
It's trading within the .0008-0012 channel so if good updates keep coming out buying will continue and hold that channel. If not, bid sitters will be rewarded.
But Aguilar seems pretty good about getting the word out. So far.
My mistake in my wording. Patents pending are enforceable from the date of the application once the patent is approved.
Granted or not, a pending patent is still enforceable.
Would be nice to have an announcement of FDA and CGMP approval along with a virtual tour of the facility prior to production start.
Also wondering how much longer before the ABBIE patent approval comes through. That should get more people off the fence.
All these announcements ought to get $SHMN thru tax loss selling season without too much damage, if any at all.
I thought it was pretty pretty well explained.
ABBIE is currently undergoing further development to optimize expression and purification of its protein-based platform. Upon completion of development, ABBIE will become high-quality, off-the-shelf cell engineering kits. Gene-editing companies will use ABBIE kits to deliver a gene payload to a specific locus on their targeted cells.
Revenue generations can be obtained immediately through licensing and gene-editing kits slated to be released for commercialization in 3Q/4Q 2024. ABBIE is expected to reach in-human trial on or before 4Q 2025.
A steady inflow of good news should soon get the PPS out of trips.
SOHM will establish offices and a wet lab bench, utilizing the best-practices environment with certified Good Laboratory Practices (GLP) to fast-track development. This flexibility will allow SOHM’s ABBIE to “rent-a-bench," expand the lab space, and accelerate growth plans.
Was wondering that myself. What popped into my head first is more equipment waiting to be unboxed and assembled. In a few days looking another vid tweet to show further progress followed by one narrated by Baron showing manufacturing in process.🤫
Why?
It clearly shows that they have FDA approved products on the market bringing in revenues.
Your post should be pinned and placed in the IBox.
ADX below 15. I've learned an ADX below 15 with +DI above D- signals a possible big up move coming.
info@sohm.com
What's the difference?
Civility helps.
As for being able to email the company, that doesn't seem to be an issue. I emailed asking what the particulars were on the funding for the ABBIE acq and this is the response I received:
That leaves me thinking the funding for ABBIE and other projects are all tied up together.
Also the lack of dilution whacking the bid like you normally see when dilution is issued and sold is worth something. At least so far.